Objectives: The semi-synthetic streptogramin quinupristin/dalfopristin antibiotic exerts potent bactericidal activity against Staphylococcus aureus. We investigated whether, like other bactericidal antibiotics used at subinhibitory concentrations, quinupristin/dalfopristin enhances release of toxins by Grampositive cocci.
Introduction
Staphylococcus aureus is one of the most common pathogens of community-acquired and nosocomial diseases with a significant morbidity and mortality. Infections due to this organism have a variety of clinical manifestations, ranging from localized skin infections to severe sepsis, including toxic-shock syndrome. 1 S. aureus produces a wide array of toxins that determine, at least in part, the pathogenesis of infection. This is exemplified by toxic-shock syndrome caused by toxic-shock syndrome toxin-1 (TSST1)-producing S. aureus or by necrotizing pneumonia and epidemic furunculosis caused by community-acquired methicillin-resistant S. aureus (cMRSA) that is often associated with Panton-Valentine leucocidin (PVL) production. 2 For the management of toxic S. aureus infections, b-lactam antibiotics proved unfavourable, because even subinhibitory concentrations (for example of methicillin) lead to an increase in a-toxin expression through a stimulatory effect on exoprotein synthesis. [3] [4] [5] Instead, protein-synthesis-suppressing antibiotics such as clindamycin and linezolid are recommended for the treatment of S. aureus-produced toxic syndromes as concentrations below the MIC have been shown to impair the expression of virulence factors of S. aureus. 6, 7 Clindamycin at a concentration of 1/8 MIC inhibits the expression of a-and d-haemolysin as well as coagulase. 8 In addition, the expression of protein A is reduced when S. aureus is exposed to clindamycin at concentrations below the MIC, leading to increased bacterial susceptibility to phagocytosis and suggesting additional therapeutic efficacy. 9 However, clindamycin cannot be used for toxic MRSA infections because MRSA are mostly resistant to clindamycin. For this reason, two new drugs, quinupristin/dalfopristin and linezolid, came into the clinics, which seem to be suitable for The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org the treatment of infections caused by multidrug-resistant Gram-positive cocci. 10 Recently, we reported that subinhibitory concentrations of linezolid downmodulate virulence factor release by S. aureus. 7 It should be noted, however, that neither linezolid nor clindamycin is expected to be effective for the treatment of S. aureus infections in neutropenic patients, which call for bactericidal rather than bacteriostatic antibiotics. In contrast to linezolid, quinupristin/dalfopristin exerts bactericidal activity against S. aureus. 11 Although quinupristin/dalfopristin appears to be a valuable alternative for MRSA infections, the action of quinupristin/dalfopristin on virulence factor release by S. aureus has not yet been investigated.
Quinupristin/dalfopristin is the first injectable streptogramin; it belongs to the macrolide-lincosamide-streptogramin (MLS) family of antibiotics. It is composed of two semi-synthetic pristinamycin derivates, quinupristin (RP57669) and dalfopristin (RP54476), in a 30:70 ratio. 10 Quinupristin and dalfopristin bind to distinct sites on the 50S subunit of the bacterial ribosome, where they act synergically to inhibit protein synthesis and exert a bactericidal effect. 12 Quinupristin/dalfopristin is active against a broad spectrum of Gram-positive pathogens including methicillinresistant staphylococci, penicillin/erythromycin-resistant streptococci and vancomycin-resistant Enterococcus faecium (VREF). 10 While the molecular mode of action of quinupristin/dalfopristin has been unravelled, little information was available about the effects of quinupristin/dalfopristin on bacterial virulence factor production.
S. aureus produces in a growth-phase-dependent manner, predominantly during the post-exponential phase of growth, a variety of different extracellular proteins including non-toxic enzymes, enzyme activators or toxins. The vast array of virulence factors produced by S. aureus include a-, b-, g-and dhaemolysins, protein A as well as leucocidin and coagulase. 1 The expression of staphylococcal genes is generally regulated in response to fluctuations in cell-population density through a process termed quorum sensing. Gram-positive bacteria use quorum-sensing communication circuits to regulate a diverse array of physiological activities, including symbiosis, competence, conjugation, antibiotic production, biofilm formation and virulence. 13 When a sufficient number of cells, a 'quorum', is present, the accumulation of released chemical signal molecules called autoinducer-peptide (AIP) leads to gene expression.
S. aureus virulence gene expression is mainly controlled by at least two global regulatory elements such as the accessory gene regulator (agr) and the staphylococcal accessory regulator (sar).
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The accessory gene regulator agr suppresses the post-exponential phase expression of cell surface binding proteins (thought to play a role in the early stages of colonization) and enhances the expression of secreted proteins (suggested to be involved in the long-term survival of the organism at the site of infection). Unlike agr the sar locus activates the synthesis of both extracellular and surface bound proteins in S. aureus. 15 Further global regulatory elements are S. aureus exoprotein expression (sae), repressor of toxin (rot) and sigma B factor (s B ). 13 In the present study we show that subinhibitory concentrations of quinupristin/dalfopristin reduce S. aureus-mediated toxicity towards infected host cells. In addition, the supernatants of quinupristin/dalfopristin-treated S. aureus elicited an attenuated inflammatory response of macrophages. By comprehensive investigations of toxin production using proteomic approaches we found that while subinhibitory quinupristin/dalfopristin efficiently impedes the secretion of most exotoxins by S. aureus, the release of few exoproteins increases.
Materials and methods

Bacterial strain and growth conditions
Quinupristin/dalfopristin was commercially obtained from Aventis (Rhône-Poulenc Rorer S.A., Madrid, Spain) as powder and diluted before the analysis with sterile water to yield a final concentration of 0.5 g/L. The methicillin-susceptible S. aureus strain ATCC 29213 was obtained from ATCC and used throughout the study. Bacteria were stored in Microbank Ò (Pro-Lab Diagnostics, Austin, USA) at -80 C. The MIC in LB broth was determined by broth microdilution according to the National Committee for Clinical Laboratory Standards (NCCLS) standard method M7-A3. For S. aureus ATCC 29213, the MIC of quinupristin/dalfopristin was 0.25 mg/L.
For each analysis bacteria were cultivated overnight at 37 C on blood agar plates, removed from the agar surface and suspended in Luria-Bertani (LB) broth and precultured at 37 C with constant shaking (200 rpm) to post-exponential growth phase (log growth OD 540 of 2). To obtain a starting OD 540 of 0.05 an aliquot of the preculture was inoculated into 200 mL of LB broth and when indicated supplemented with quinupristin/dalfopristin at concentrations of 12.5%, 25%, 50%, 75% and 90% MIC. Bacteria were further cultured at 37 C with constant shaking under aerobic conditions. The growth of cells was monitored by reading the OD 540 values. Supernatants were harvested at four defined culture conditions: (I) quinupristin/dalfopristin was added from the beginning of culture and supernatants were harvested in the exponential phase of growth; (II) quinupristin/dalfopristin was added from the beginning of culture and supernatants were harvested in the post-exponential phase of growth; (III) bacteria were first grown to OD 540 = 0.2, then quinupristin/dalfopristin was added and supernatants were harvested in the early stationary phase of growth; (IV) bacteria were first grown to OD 540 = 0.4, then quinupristin/dalfopristin was added and supernatants were harvested in the early stationary phase of growth.
Exoprotein preparation
After indicated growth phases, supernatants of bacterial cultures were harvested. Bacteria were pelleted by centrifugation at 8500 g for 25 min at 4 C. The culture supernatant was precipitated by adding 100% trichloroacetic acid (TCA, Sigma) to a final concentration of 10%. After incubation at 4 C overnight, the precipitate was centrifuged at 8500 g for 70 min at 4 C and finally washed with icecold 100% ethanol three times and then with ice-cold 70% ethanol. The aggregated proteins were air-dried for 30 min and dissolved in 0.5 mL of 8 M urea. The protein concentration was determined by a Bio-Rad protein assay kit (Bio-Rad Corporation, Munich, Germany) according to the instructions of the manufacturer.
SDS-PAGE
One-dimensional denaturing SDS-PAGE was performed with 10% polyacrylamide gels in a Bio-Rad Protean-II electrophoresis system. The gels were stained overnight in Novex Ò Colloidal Blue staining kit (Invitrogen, Carlsbad, California, USA). Alternatively, silver staining was performed according to the method described by Shevchenko et al. 16 The slight decrease in overall protein secretion caused by quinupristin/dalfopristin was corrected by loading equal amounts of proteins. In-gel-preparation of tryptic peptides
In-gel-digestion with trypsin was performed according to standard protocols 16, 19 with minor modifications. Coomassie-stained protein bands were excised from the gel and washed three times for 10 min with water (HPLC grade, Merck Darmstadt Germany). Reduction was performed with 0.1 M Tris (pH 8.5), 0.01 M EDTA, 6 M GuHCL and 25 mM DTT for 30 min at 37 C, and the proteins were subsequently alkylated with 125 mM iodoacetamide in the dark for an additional 1 h at 37 C. Gel pieces were equilibrated twice with 100 mL of 50 mM NH 4 HCO 3 (pH 7.8) for 10 min, shrunk with 100 mL of acetonitrile, rehydrated with 100 mL of 50 mM NH 4 HCO 3 (pH 7.8) and finally shrunk again with acetonitrile. After air-drying, gel pieces were reswollen in a digestion buffer, containing 20 mL of 50 mM NH 4 HCO 3 , and 0.05 mg of trypsin (Promega, Madison, USA) at 37 C for 16 h. Peptides were extracted by subsequent incubation for 20 min at room temperature with 50 mM NH 4 HCO 3 , 0.1% TFA and finally 0.1% TFA/ acetonitrile (2:3, v/v). The pellet was dissolved in 10 mL of 0.1% TFA.
MALDI-TOF/mass spectrometry
Aliquots of 0.5 mL of the combined extract were used for MALDI mass spectrometry to obtain MS-fingerprints. Mass spectra were obtained with the Bruker REFLEX IV mass spectrometer (BrukerDaltonik, Bremen, Germany). The validation of all data obtained, including averaging of the time-of-flight data, recalibration on trypsin signals, as well as all further data processing, was carried out using the XMASS 5.1.5 post-analysis software.
Database searching
Proteins were identified from MALDI-fingerprint data using a locally installed MASCOT for web search (Matrix Science, Boston, USA) against S. aureus proteins extracted from public database (NCBI) or using the data obtained from S. aureus genome sequencing projects (The Institute for Genomic Research, Oklahoma University and Sanger Centre).
Western-blot
Western-blot analysis was performed as described previously. 7 Antibodies to S. aureus enterotoxins A (SEA) and B (SEB), ahaemolysin and protein A were purchased from Sigma Aldrich.
Tumour necrosis factor (TNF) release assay
An overnight culture of ATCC 29213 in DMEM (Biochrom) was diluted 30-fold in pre-warmed 1000 mL DMEM, incubated for 30 min at 37 C under constant shaking and divided into aliquots of 200 mL. Graded concentrations of quinupristin/dalfopristin (12.5%, 25%, 50% and 90% MIC) were added to the diluted bacterial suspensions before incubation for a further 4 h. S. aureus supernatants without antibiotic treatment and uninoculated medium served as controls. Proteins secreted into the supernatants were filtered through a 0.2 mm pore-size-filter (Braun Melsungen AG, Germany) and immediately analysed as described below. C57BL/6 mice (Charles River Wiga, Sulzfeld, Germany) were kept under specific pathogens free conditions and used when 6-10 weeks old. Animal experiments were approved by the Ethics Committee of Cologne Government and were performed according to German law. Resident peritoneal macrophages were harvested by rinsing the peritoneal cavity with chilled 0.9% NaCl. Cells were seeded at a density of 10 6 /mL in DMEM, 5% FCS without antibiotics, into 96-well flat tissue culture plates (Nunc, Kamstrup, Denmark) and incubated in 5% CO 2 at 37 C for 1 h to allow adherence. Nonadherent cells were removed by aspiration before bacterial filtrates were added to the adherent cells. After incubation for 6 h the supernatants were collected, centrifuged (1000 g for 5 min) and stored at -70 C. TNF concentration in the supernatants was determined using Mouse TNF-a DuoSet ELISA (R&D Systems Inc., Minneapolis, MN, USA) according to the instructions of the manufacturer.
Cytotoxicity assay for S. aureus-infected host cells
The mouse fibroblast mKSA cell line was cultured in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10% heatinactivated fetal calf serum, 10 5 U/L penicillin G and 100 mg/L streptomycin sulphate (all from Biochrom, Berlin, Germany), and 18 h prior to infection, 5 · 10 5 cells were seeded in 6-well plates (total volume = 3 mL) (Nunc, Wiesbaden, Germany). Viability was monitored using Trypan Blue (Biochrom) exclusion. Prior to infection, cells were washed with growth medium without antibiotics and kept for 1 h at 37 C. S. aureus (1·10 7 cfu) grown in the presence of quinupristin/dalfopristin at 12.5%, 50%, 75% or 90% MIC were added to produce an m.o.i. of 50. After 1 h of incubation cells were washed with growth medium. Extracellular staphylococci were killed by incubation with 100 mg/L lysostaphin (Sigma) for 7 min at 37 C. This treatment was found to be effective in eradicating all extracellular S. aureus. Cells were washed with growth medium complemented with penicillin/streptomycin and reseeded in new 2 mL cultures. After 24 h of incubation, cells were harvested and analysed by microscopy. Host cell viability was measured using Trypan Blue exclusion.
Statistical analysis
Experimental data were assessed with a two-tailed unpaired Student's t-test for comparison between means. P values of <0.01 were considered to be statistically significant.
Results
Reduced inflammatory potential of S. aureus supernatants treated with subinhibitory concentrations of quinupristin/dalfopristin Secreted proteins of S. aureus are known to stimulate cells of the immune system such as macrophages resulting in the release of TNF and other proinflammatory cytokines. In addition, bactericidal antibiotics such as penicillins induce release of endogenous factors by Staphylococci 20 that activate macrophages via stimulation of toll-like receptors (TLRs). To address the proinflammatory potential of quinupristin/dalfopristin we studied TNF release from peritoneal macrophages incubated with S. aureus culture supernatants previously treated with graded concentrations of quinupristin/dalfopristin. As shown in Figure 1 , the supernatant of untreated S. aureus induced a high level of TNF secretion, which was comparable to the TNF release induced by lipopolysaccharide (LPS) from Salmonella enterica serovar Typhimurium, a strong agonist of TLR4. Treatment of macrophages with the supernatants of S. aureus grown with quinupristin/dalfopristin at concentrations of 50% and 90% of the MIC inhibited the release of TNF in a dose-dependent manner.
Reduction of host cell cytotoxicity of intracellular S. aureus by quinupristin/dalfopristin S. aureus is able to enter, survive and induce cell death in several non-professional phagocytes. 21 The killing of host cells by intracellular S. aureus involves presumably one or several exoproteins secreted in the host phagosome. To address the question of whether quinupristin/dalfopristin can modulate S. aureus-mediated cytotoxicity we used as a eukaryotic host cell a murine fibroblast cell line, mKSA, that has been previously successfully employed to analyse the intracellular activity of S. aureus. 22 Infection of mKSA cells with untreated S. aureus resulted in death of 80% of the host cells within 24 h after infection ( Figure 2 ). When mKSA cells were infected with S. aureus cultured in the presence of graded subinhibitory concentrations of quinupristin/dalfopristin, the rate of host cell death dramatically decreased from 78% to 36% at a quinupristin/ dalfopristin concentration of 50% MIC. Similar effects on cytotoxicity were observed for clindamycin, which is known to inhibit virulence factor production at sub-MIC concentrations. 6, 8, 23 In contrast, host cell viability was not significantly improved when S. aureus was previously cultured in the presence of linezolid at concentrations up to 90% MIC prior to infection.
Effects of sub-MIC quinupristin/dalfopristin on protein secretion by S. aureus and protein identification
The decreased TNF-releasing activity found in the supernatants and the decreased cytotoxicity of S. aureus previously treated with subinhibitory concentrations of quinupristin/dalfopristin suggested that quinupristin/dalfopristin down-regulates the production and/or release of S. aureus virulence factors. To differentiate quinupristin/dalfopristin-related modulation of virulence factor production from effects secondary to growth arrest or quorum-sensing phenomena, we addressed quinupristin/ dalfopristin action on S. aureus at distinct growth phases.
S. aureus ATCC 29213 cultures were treated from the start of growth (OD 540 = 0.05) with graded concentrations of quinupristin/ dalfopristin (0%, 12.5%, 25%, 50% and 90% MIC). Bacterial growth was monitored for 8.5 h. As expected a dose-dependent attenuation of bacterial growth was observed (Figure 3a) . When S. aureus was exposed to subinhibitory concentrations of quinupristin/dalfopristin from the start of growth and harvested Mean values from three independent experiments -SD. b I-IV refer to the harvesting conditions described in the Materials and methods section. Quinupristin/dalfopristin reduces virulence of S. aureus 569 before quorum sensing, that is at OD 540 < 0.8, quinupristin/ dalfopristin slightly reduced the secretion of proteins into the supernatants in a dose-dependent manner (Table 1 and Figure 3b ). To examine possible effects of quinupristin/dalfopristin on the bacterial release of proteins, supernatants of bacterial cultures were harvested at the exponential and the post-exponential phase of bacterial growth. Coomassie Blue stained bands were subjected to MALDI-TOF/MS analysis and subsequent identification. The matches of peptide masses and the sequence coverage allowed the identification of 39 proteins including the 33 proteins previously described by Bernardo et al. 7 (Table 2 ). When the supernatants of S. aureus cultures were harvested in the post-exponential phase of bacterial growth, a significant accumulation of low molecular weight proteins was observed with quinupristin/dalfopristin at a concentration of 90% MIC (Figure 3b and c) . These proteins were identified as ribosomal proteins (Rpl, Rpm, Rps families). Furthermore the secretion of the stress-inducible protein DnaK was enhanced. In contrast, the release of virulence factors a-and b-haemolysins (Hla, Hlb), proteins of the autolysin family (Atl) and lipases (Lip, Geh), and the secretory antigen precursor SsaA homologue was reduced, while the secretion of the protein A (SpA) remained unchanged. Interestingly, the secretion of autolysin, lipases and enolase (Eno) showed a biphasic response, in that these proteins were increased by quinupristin/dalfopristin at concentrations below 50% MIC, but were down-regulated by quinupristin/dalfopristin at 90% MIC.
With the exception of prophylactic antibiotic therapy, antibiotics are administered when bacterial infections produce clinical symptoms. It was, therefore, important to investigate the effects of quinupristin/dalfopristin added to S. aureus cultures at a later stage of bacterial growth (OD 540 = 0.2 and OD 540 = 0.4).
As shown in (Figure 4a ) the anti-proliferative effects of quinupristin/dalfopristin on S. aureus growth were less pronounced. When added at early log phase (OD 540 of 0.2) quinupristin/dalfopristin affected the release of some exoproteins more than others (Figure 4b ). For example, the secretion of a-and b-haemolysins (Hla and Hlb) is more impaired than that of protein A (SpA), lipases (Lip, Geh) or mature autolysin (Atl).
We next employed 2D gel electrophoresis to confirm the changes of protein profiles at higher resolution. Approximately 100 protein spots were separated by 2D gel electrophoresis in a molecular range between 10 and 80 kDa and a pI range between 3.5 and 10. In general, the protein profiles obtained by 2D gel analysis corresponded to those obtained by 1D SDS-PAGE yet allowed us to distinguish changes of expression of proteins with similar molecular weight.
For example, when the same protein samples previously separated by 1D SDS-PAGE were analysed by 2D gels, the changes in the protein profiles of Figure 5 (a-e) are comparable to the changes in the protein bands of Figure 4 (b). For some proteins such as triacylglycerol lipase (Lip) and DnaK a biphasic response was observed. Intermediary concentrations of quinupristin/ dalfopristin (25-50% MIC) increased, while quinupristin/ dalfopristin at 90% MIC diminished triacylglycerol lipase (Lip) and DnaK expression (Figure 5a-e) . In contrast, the production of the a-and b-haemolysins (Hla, Hlb) and to a lesser extent protein A (Spa) is dose-dependently reduced.
Addition of quinupristin/dalfopristin in the mid-log phase (OD 540 of 0.4) also resulted in the attenuation of S. aureus growth accompanied by a decrease in exoprotein release in a similar pattern ( Figure 6 ). However the impact of both growth rate and the release of extracellular proteins was significantly less pronounced compared with harvesting conditions III. 2D gel analysis revealed the absence of the biphasic response of Lip and DnaK, which was observed previously (Figure 7a-e) . Instead, a release profile of these proteins showed dose-dependent downregulation. In addition, inhibition of the release of other exoproteins required a higher quinupristin/dalfopristin dose, for example the same level of SpA down-regulation by 50% MIC of quinupristin/dalfopristin (Figure 5c ) was first observed at 75% of quinupristin/dalfopristin (Figure 7d ). SEA and SEB could not be identified unambiguously by 2D SDS-PAGE/MALDI-TOF/MS probably due to their low concentrations in S. aureus supernatants. In order to visualize the effects of quinupristin/dalfopristin on SEA and SEB secretion, western-blot analysis was performed. As shown in Figure 8 (a-c) , addition of quinupristin/dalfopristin before quorum sensing resulted in the inhibition of a-haemolysin, SEA, SEB and protein A in a dose-dependent manner. Addition of quinupristin/ dalfopristin at later time points in the mid-logarithmic phase caused reduced release of a-haemolysin, SEA and SEB (Figure 8d ).
Discussion
The pathogenicity of S. aureus, like that of other Gram-positive bacteria, depends largely on extracellular virulence factors. The clinical efficacy of antibiotics is not only determined by their respective bactericidal or bacteriostatic activity and pharmacokinetics but also by their action on virulence factor release. In general, antibiotic-induced release of exotoxins can enhance S. aureus-related toxic syndromes as well as proinflammatory host responses, while down-regulation of exotoxins expression causes a significant attenuation of virulence. In particular, cellwall-affecting bactericidal antibiotics not only increase the release of endotoxin and exotoxin by destroying bacterial integrity but also stimulate exotoxins to be released at subinhibitory concentrations. 24 For example, b-lactams and glycopeptides induce alpha toxin expression through a stimulatory effect on exoprotein synthesis. 3 On the other hand, the synthesis of many staphylococcal exoproteins, including virulence factors, is inhibited by subinhibitory concentrations of antibiotics whose mode of action is to block protein synthesis. The fact that quinupristin/ dalfopristin inhibits protein synthesis yet exerts bactericidal activity towards S. aureus raised the question about its possible action on virulence factor release by S. aureus.
In the present study we demonstrate that quinupristin/ dalfopristin dose-dependently reduces both the induction of TNF-releasing activity by, and the toxicity of, S. aureus towards host cells. These two phenotypic consequences of quinupristin/ dalfopristin action on S. aureus indicate the overall downregulation of S. aureus virulence, because (i) the TNF-releasing (Table 2) .
activity represents the sum of S. aureus proinflammatory exotoxins able to stimulate macrophages and (ii) host cell toxicity has been previously associated with tissue penetration and invasiveness of S. aureus. It is important to note that the TNF release assay and the host cell toxicity assay, respectively, seem to represent two functionally distinct, only partially overlapping sets of exotoxins. In this respect the comparison between quinupristin/ dalfopristin and linezolid is instructive. Linezolid was recently found to inhibit the production of TNF-releasing activity by S. aureus at concentrations of 12.5% MIC 7 and hence is more effective than quinupristin/dalfopristin that down-regulated TNFreleasing activity only at 50% MIC. In contrast, linezolid was essentially ineffective in reducing the cytotoxicity of S. aureus, while quinupristin/dalfopristin decreased S. aureus-mediated cytotoxicity at 50% MIC. These findings suggest that like linezolid subinhibitory quinupristin/dalfopristin attenuates the inflammatory host response, yet in addition impairs S. aureus cytotoxicity, which might be of particular importance for the treatment of invasive S. aureus infections.
The proteomic analysis of quinupristin/dalfopristin effects on exotoxin release revealed a non-uniform response. When added from the start of culture, quinupristin/dalfopristin dosedependently reduced the expression of most exotoxins within a culture period of 1.5 h. However, when cultured for 3 h, some exoproteins showed a biphasic response. For example, autolysin, triacylglycerol lipase and NAG were induced at 12.5%, 25% and 50% MIC quinupristin/dalfopristin and repressed at 90% MIC quinupristin/dalfopristin. This can be explained by secondary effects caused by growth retardation in the presence of 90% MIC quinupristin/dalfopristin, by enhanced transcriptional activity, as shown for clindamycin, 25 or by quinupristin/dalfopristin consumption by S. aureus during prolonged culture, which might become evident only when quinupristin/dalfopristin is added at low concentrations. At any rate, the biphasic induction of select exotoxins obviously did not impact on the overall TNFreleasing activity or cytotoxicity produced by S. aureus. The phenotypic reduction of S. aureus virulence, in fact, corresponded well with the dose-dependent down-regulation of established virulence factors such as haemolysin-a, SEA, SEB and protein A. When added at later growth phases, quinupristin/dalfopristin did not significantly influence the growth rate of S. aureus. At 90% MIC, quinupristin/dalfopristin reduced the expression of select exotoxins, whereas a number of exoproteins remained unchanged and biphasic responses were hardly detectable.
We have recently reported on reduction of S. aureus virulence factor expression by subinhibitory concentrations of linezolid. 7 As shown by proteomic analysis linezolid reduced in a dosedependent manner the secretion of specific virulence factors, including SEA, SEB, autolysin, protein A, and a-and bhaemolysins. In contrast, other presumably non-toxic exoproteins remained unchanged or even accumulated in supernatants in the presence of linezolid at 90% MIC. While the overall response to linezolid seems to be similar to that observed with quinupristin/ dalfopristin, distinct differences of exoprotein expression could be discerned. For example, triacylglycerol lipase, glycerol ester hydrolase, glycerophosphoryl diester phosphodiesterase and glyceraldehyde-3-phosphate dehydrogenase were up-regulated by subinhibitory linezolid but down-regulated by subinhibitory quinupristin/dalfopristin.
Herbert et al. 25 reported that subinhibitory clindamycin differentially inhibits transcription of exoprotein genes in S. aureus. In conjunction with our own observations with linezolid, the mainly inhibitory action of subinhibitory quinupristin/dalfopristin on exoprotein release was not expected. With regard to clindamycin, the differential inhibitory effects on gene transcription were suggested to be secondary to the inhibition of translation of one or more global regulatory mRNAs. 25 Indeed, many genes encoding virulence genes are coordinately regulated in response to a variety of intracellular and extracellular signals. It is well established that antibiotics of different structure and known inhibitory activity are able to stimulate different promoters when bacteria are exposed to subinhibitory concentrations of the drugs. 3, 25, 26 A variety of chromosomal gene promoters are activated, including those involved in virulence, metabolic and adaptive functions. The extent and magnitude of the effects observed suggest that the transcriptional modulation by commonly used antibiotics could lead to negative consequences during the treatment of bacterial infections in human hosts. The up-regulation of global virulence regulators by low concentrations of antibiotics would lead to the activation of bacterial regulons, including the production of virulence factors in pathogens.
It is tempting to speculate that quinupristin/dalfopristininduced inhibition of global regulators such as agr or sarA might result in the decreased virulence factor secretion. However, the pattern of individual exotoxins reduced in the presence of quinupristin/dalfopristin is not consistent with the pattern to be expected after inactivation of specific global regulator(s). For example, quinupristin/dalfopristin reduced protein A expression at any growth phase tested. If the primary effect of quinupristin/ dalfopristin was to decrease expression of the octapeptide regulating agr expression, then protein A expression would be expected to be increased rather than decreased. Taken together, the proteomic analysis of S. aureus exotoxins revealed a robust down-regulation of release of exotoxins by subinhibitory quinupristin/dalfopristin, which explains the downmodulating action of subinhibitory quinupristin/dalfopristin on S. aureus virulence in vitro.
